186 related articles for article (PubMed ID: 18536554)
1. Antibody engineering principles and applications.
Loo L; Robinson MK; Adams GP
Cancer J; 2008; 14(3):149-53. PubMed ID: 18536554
[TBL] [Abstract][Full Text] [Related]
2. Engineered antibodies take center stage.
Huston JS; George AJ
Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424
[TBL] [Abstract][Full Text] [Related]
3. Antibodies and genetically engineered related molecules: production and purification.
Roque AC; Lowe CR; Taipa MA
Biotechnol Prog; 2004; 20(3):639-54. PubMed ID: 15176864
[TBL] [Abstract][Full Text] [Related]
4. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies, antigens and molecular diagnostics: a practical overview.
Laurino JP; Shi Q; Ge J
Ann Clin Lab Sci; 1999; 29(3):158-66. PubMed ID: 10440578
[TBL] [Abstract][Full Text] [Related]
6. Antibody engineering: an overview.
O'Kennedy R; Roben P
Essays Biochem; 1991; 26():59-75. PubMed ID: 1778186
[TBL] [Abstract][Full Text] [Related]
7. Novel antibodies as anticancer agents.
Zafir-Lavie I; Michaeli Y; Reiter Y
Oncogene; 2007 May; 26(25):3714-33. PubMed ID: 17530025
[TBL] [Abstract][Full Text] [Related]
8. Engineering antibodies for clinical applications.
Jain M; Kamal N; Batra SK
Trends Biotechnol; 2007 Jul; 25(7):307-16. PubMed ID: 17512622
[TBL] [Abstract][Full Text] [Related]
9. Engineered affinity proteins for tumour-targeting applications.
Friedman M; Ståhl S
Biotechnol Appl Biochem; 2009 May; 53(Pt 1):1-29. PubMed ID: 19341363
[TBL] [Abstract][Full Text] [Related]
10. Historical development of monoclonal antibody therapeutics.
Nissim A; Chernajovsky Y
Handb Exp Pharmacol; 2008; (181):3-18. PubMed ID: 18071939
[TBL] [Abstract][Full Text] [Related]
11. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function.
Presta LG
Adv Drug Deliv Rev; 2006 Aug; 58(5-6):640-56. PubMed ID: 16904789
[TBL] [Abstract][Full Text] [Related]
12. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development.
Mascelli MA; Zhou H; Sweet R; Getsy J; Davis HM; Graham M; Abernethy D
J Clin Pharmacol; 2007 May; 47(5):553-65. PubMed ID: 17379759
[TBL] [Abstract][Full Text] [Related]
13. [Monoclonal antibodies in the treatment of neoplastic hematologic diseases].
Coiffier B
Bull Cancer; 2000 Nov; 87(11):839-45. PubMed ID: 11125292
[TBL] [Abstract][Full Text] [Related]
14. Antibody engineering and modification technologies.
Filpula D
Biomol Eng; 2007 Jun; 24(2):201-15. PubMed ID: 17466589
[TBL] [Abstract][Full Text] [Related]
15. Multivalent antibodies: when design surpasses evolution.
Cuesta AM; Sainz-Pastor N; Bonet J; Oliva B; Alvarez-Vallina L
Trends Biotechnol; 2010 Jul; 28(7):355-62. PubMed ID: 20447706
[TBL] [Abstract][Full Text] [Related]
16. Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells.
Silva HM; Vieira PM; Costa PL; Pimentel BM; Moro AM; Kalil J; Maranhão AQ; Coelho V; Brigido MM
Immunol Lett; 2009 Aug; 125(2):129-36. PubMed ID: 19573559
[TBL] [Abstract][Full Text] [Related]
17. Antibody engineering--IBC's Tenth International Conference. 6-9 December 1999, La Jolla, CA, USA.
Carter P
IDrugs; 2000 Mar; 3(3):259-61. PubMed ID: 16103927
[TBL] [Abstract][Full Text] [Related]
18. Future applications of biotechnology in poultry.
Purchase HG
Avian Dis; 1986; 30(1):47-59. PubMed ID: 3015108
[TBL] [Abstract][Full Text] [Related]
19. Molecular engineering and design of therapeutic antibodies.
Presta LG
Curr Opin Immunol; 2008 Aug; 20(4):460-70. PubMed ID: 18656541
[TBL] [Abstract][Full Text] [Related]
20. Human anti-ErbB2 immunoagents--immunoRNases and compact antibodies.
De Lorenzo C; D'Alessio G
FEBS J; 2009 Mar; 276(6):1527-35. PubMed ID: 19220462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
